Clinical Trials in Jiangyin, China
2 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled194 locationsNCT07190222
Recruiting
Phase 3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Colorectal Neoplasms
Merck Sharp & Dohme LLC100 enrolled32 locationsNCT05239741
Recruiting
Not Applicable
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
HypothermiaCancer SurgeryDelirium+1 more
Peking University First Hospital3,992 enrolled36 locationsNCT06256354
Recruiting
Phase 3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled70 locationsNCT07165951
Recruiting
Phase 3
Metformin Treatment on Cognitive Impairment of Schizophrenia
Schizophrenia
Central South University120 enrolled4 locationsNCT05838573
Recruiting
Phase 2
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
Non Alcoholic Steatohepatitis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.120 enrolled53 locationsNCT06569524
Recruiting
Phase 3
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Community-acquired Bacterial Pneumonia
Zai Lab (Hong Kong), Ltd.100 enrolled40 locationsNCT06162286
Recruiting
Phase 2
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled44 locationsNCT05678270